UBXG vs RNAZ Comparison

U-BX Technology Ltd is focused on providing value-added services using artificial intelligence-driven technology to businesses within the insurance industry, including insurance carriers and brokers. It helps institutional clients obtain visibility on various social media platforms and generate revenue based on consumers' clicks, views, or its clients' promotion time through those channels. The company derives a majority of its revenue by providing digital promotion services to its clients and also engages in providing risk assessment services, and value-added bundled benefits. It has developed an algorithm named Magic Mirror, to calculate payout risks for insurance carriers to underwrite auto insurance coverage. Geographically, all of the company's revenue is derived from Mainland China.

TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.